Tribute Pharmaceuticals and Faes Farma Announce Exclusive License Agreement in Canada for Bilastine, a New Treatment Option in

Tribute Pharmaceuticals and Faes Farma Announce Exclusive License Agreement in 
Canada for Bilastine, a New Treatment Option in the $120 million Allergic 
Rhinitis and Urticaria Market 
FOR: Tribute Pharmaceuticals Canada Inc. 
MAY 13, 2014 
Tribute Pharmaceuticals and Faes Farma Announce Exclusive License Agreement in
Canada for Bilastine, a New Treatment Option in the $120 million Allergic
Rhinitis and Urticaria Market 
MILTON, ONTARIO and MADRID, SPAIN--(Marketwired - May 13, 2014) - Tribute
Pharmaceuticals Canada Inc. ("Tribute")
pharmaceutical company) and Faes Farma, S.A. ("Faes") (BME:FAE), a
Spanish pharmaceutical company, announced today the signing of an exclusive
license agreement that grants Tribute the exclusive right to sell Faes's
Bilastine product for the treatment of Allergic Rhinitis and Chronic Idiopathic
Urticaria (hives) in Canada, following receipt of regulatory approval from
Health Canada for such product. The exclusive license is inclusive of
prescription and non-prescription rights for Bilastine, as well as adult and
paediatric presentations in Canada. Terms of the agreement were not disclosed. 
Allergic rhinitis and urticaria are both allergic disorders that can adversely
affect quality of life to the extent that work or school productivity may be
impairedi. The characteristic symptoms of allergic rhinitis are nasal itching,
congestion, rhinorrhoea and sneezingii. For urticaria, characteristic symptoms
include itchy skin lesions with a central swelling (wheals) and painful areas
of deeper swelling involving the skin and mucous membranes (angioedema)iii.
Both types of allergies are common, with a global prevalence of 10-30% for
allergic rhinitis and of greater than 20% for urticariaiv. Even though the cost
of care for individuals with allergic disorders is low, the total global cost
is high, predominantly because these disorders are so highly prevalentv.
According to the Canadian Allergy, Asthma and Immunology foundation, Allergic
Rhinitis affects 20% to 25% of Canadiansvi. 
IMS Health reports that the Canadian oral antihistamines market had sales of
approximately $120 million in 2013. Upon approval by Health Canada, Bilastine
will be the first new oral antihistamine approved in Canada since 2001.
Bilastine will provide Allergists, Immunologists, Dermatologists, Family
Medicine and General Practitioners a new treatment option for allergic rhinitis
and chronic idiopathic urticaria with a clinically proven safety and efficacy
Mariano Ucar, President and CEO of Faes commented, "Faes shall have the
opportunity to provide Canadian patients direct access to the innovative
Bilastine drug, in the allergy and dermatology fields. The Canadian
pharmaceutical business is a top 10 pharmaceutical market globally. Bilastine
is an excellent fit with Tribute's sales and marketing infrastructure and
presence in Canada. We have found an excellent partner for Canada and look
forward to a successful commercial launch". 
"We are excited to have the opportunity to launch a globally recognized
product like Bilastine in Canada, and to further strengthen our dermatology and
primary care portfolio," said Rob Harris, President and CEO of Tribute.
"Bilastine has been approved in 48 countries worldwide and we look forward
to introducing this new and innovative product to Canadian physicians.
Furthermore, the execution of this agreement underscores Tribute's
commitment to expanding its business in Canada with licensed, long-term,
patent-protected, revenue generating products like Bilastine, while also
acquiring and licensing mature products in Canada. Bilastine is a great
opportunity for Tribute because it also provides us with the ability to
maximize a longer-term revenue source with an over-the-counter strategy as
Tribute plans to host a conference call on Thursday, May 15, 2014 at 11:00 AM
EDT or 8:00 AM PDT to further discuss the Bilastine license in conjunction with
a review and discussion of the Company's results for the first quarter
ending March 31, 2014. Details of this call were announced on May 8, 2014. 
About Bilastine 
Bilastine is a non-sedating H1-antihistamine for symptomatic treatment of
Allergic Rhinitis and Urticaria in adults and children older than 12 years of
age. It is an innovative and patent protected new molecule developed by Faes in
Spain. Bilastine, as a new active substance in Canada, will be granted a
minimum of 8 years market exclusivity upon Health Canada approval. Bilastine
has been studied in over 30 clinical trials including 5 pivotal Phase III
trials in Allergic Rhinitis or Urticaria. Bilastine has been licensed for 126
countries worldwide and is marketed by Faes (BME:FAE), Menarini,
GlaxoSmithKline, Pfizer, Takeda, Pierre Fabre, Merck KGaA, Hikma Taiho and
About Faes Farma S.A. 
Faes Farma was established in Bilbao, Spain in 1933. Today, Faes remains a
Spanish company with a global focus that researches, manufactures and markets
pharmaceutical products and raw materials in over 60 countries worldwide. Faes
has offices, R&D and manufacturing facilities in Spain and Portugal as well
as sales and marketing infrastructure in Latin America. In 2013, Faes employed
over 700 people and had sales revenues of approximately EUR180 million. For
further information about Faes, visit 
About Tribute Pharmaceuticals Canada Inc. 
Tribute is a Canadian specialty pharmaceutical company focused on the
acquisition, licensing, development and management of pharmaceutical and
healthcare products with its primary focus on the Canadian and US markets.
Tribute markets Cambia(R)(ii) (diclofenac potassium for oral solution),
Bezalip(R)(i) SR (bezafibrate), Soriatane(R)(i) (acitretin), NeoVisc(R) (1.0%
sodium hyaluronate solution) Uracyst(R) (sodium chondroitin sulfate solution
2%) and Collatamp G(R)(iii) in the Canadian market. Additionally, NeoVisc(R)
and Uracyst(R) are commercially available and are sold globally through various
international partnerships. 
For further information on Tribute visit the Company's website: 
Tribute Pharmaceuticals Forward Looking Statement 
This press release contains certain forward-looking statements about Tribute as
defined in the Private Securities Litigation Reform Act of 1995, which
statements can be identified by the use of forward-looking terminology, such as
"may", "will", "expect", "intend",
"anticipate", "estimate", "predict",
"plan" or "continue" or the negative thereof or other
variations thereon or comparable terminology referring to future events or
results. Forward- looking statements, by their nature, are subject to risks and
uncertainties, Tribute's actual results could differ materially from those
anticipated in these forward looking statements as a result of numerous
factors, including general economic conditions, the ability of Tribute to
successfully integrate operations, and the timing of expenditures and expansion
opportunities, any of which could cause actual results to vary materially from
current results or anticipated future results. Specifically in respect of this
release there is no certainty that Tribute will be able to obtain Health Canada
approval for Bilastine or, if approved, that Tribute will be able to
successfully market Bilastine. See Tribute's reports filed with the
Canadian Securities Regulatory Authorities and the U.S. Securities and Exchange
Commission including Tribute's Form 10-K for the fiscal year ended
December 31, 2013, which contains cautionary statements identifying important
risk factors with respect to such forward-looking statements, including certain
risks and uncertainties that could cause actual results to differ materially
from results referred to in any forward-looking statements. Tribute assumes no
obligation to update the information contained in this press release to update
forward-looking statements to reflect changed assumptions, the occurrence of
anticipated events or changes in future operating results, financial condition
or business over time. 
(i)Soriatane and Bezalip are registered trademarks and under license from
Actavis Group PTC ehf  
(ii)Cambia is a registered trademark and under license from Depomed, Inc. 
(iii)Collatamp G(R) is a registered trademark and under license from EUSA
Pharma (Europe) Limited. 
i.  Carter N J, Bilastine In Allergic Rhinitis and Urticaria. Drugs 2012; 72 
(9); 1257-1269. 
ii. Ibid 
iv. Ibid 
v.  Ibid 
vi. The Canadian Allergy, Asthma and Immunology Foundation n.d., Allergies 
Asthma Our research is helping your loved ones., pamphlet.  
Tribute Pharmaceuticals Canada Inc.
Scott Langille
Investor Relations
Nuwa Group LLC
Kevin Fickle
(925) 330-8315 
INDUSTRY:  Medical and Healthcare - Medical Devices, Pharmaceuticals and
Biotech - Equipment and Supplies 
-0- May/13/2014 21:00 GMT
Press spacebar to pause and continue. Press esc to stop.